‘Revolutionary’ discovery about type of liver cancer

New investigation”can make a revolution“Treatment of cholangiocarcinoma (KCA), extremely aggressive and from difficult care. And researchers from the University of Sima in Navarre, together with the Network Center for Biomedical Research in Liver and Digestive Diseases (CIBEREHD), have identified new epigenetic target which could shed light on this disease.

“Cholangiocarcinoma is one of the biggest therapeutic challenges in oncologysince current treatments offer limited effectiveness. Research team identifies promising therapeutic target: enzyme PRMT5which plays a crucial role in the progression of OSA. This discovery opens up new possibilities for creating more effective treatments,” he said. CYBER in the statement.

To take into account

Among other things, the study showed that the enzyme PRMT5levels of which are high in patients with CCA and are associated with more severe disease. advancedcan be blocked using drugs already approved for other types of tumors.

And thanks to this, tumor cell growth is stoppedsaid CIBEREHD Principal Investigator, Research Director and Co-Director of the Cima Solid Tumors Program, Matias Avila.

More details

As if that weren’t enough, experts also noted that combination of these drugs And traditional chemotherapy “significantly enhanced the antitumor effect”, demonstrating “great therapeutic potential”, which was confirmed in CCA models mouse.

Without a doubt, these discoveries can give way -both in the short and long term – to new clinical trials, which, in turn, can significantly improve the treatment of this disease.

Results of a study in which specialists took part Italy, Poland and Germanywere published in the British magazine ‘intestine‘and they contribute’new hope for the fight against a disease whose incidence has been growing in recent years.“.